ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

10064	Companies
205720	Keywords
135960	Articles
109067	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 10/07/2024 at 22:01, 1 year 5 months ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
Abivax congratulates Victor Ambros and Gary Ruvkun on their Nobel Prize for the discovery of microRNA and its role in post-transcriptional gene regulation

Abivax MicroRNA Nobel Prize Victor Ambros Gary Ruvkun
PRESS RELEASE

published on 10/07/2024 at 22:01, 1 year 5 months ago

Abivax félicite Victor Ambros et Gary Ruvkun pour leur prix Nobel, récompensant leur découverte du microARN et son rôle dans la régulation post transcriptionnelle des gènes
Abivax félicite Victor Ambros et Gary Ruvkun pour leur prix Nobel concernant la découverte du microARN et sa régulation post-transcriptionnelle des gènes. Réactions et objectifs d'Abivax pour l'avenir

Abivax Rectocolite Hémorragique MicroARN Prix Nobel Innovation Thérapeutique
BRIEF

published on 10/03/2024 at 22:06, 1 year 5 months ago

Abivax recrute un premier patient pour son essai clinique sur la maladie de Crohn

Biotechnologie Abivax Obefazimod Maladie De Crohn Essai Clinique
BRIEF

published on 10/03/2024 at 22:06, 1 year 5 months ago

Abivax recruits first patient for its clinical trial on Crohn's disease

Biotechnology Abivax Obefazimod Clinical Trial Crohn's Disease
PRESS RELEASE

published on 10/03/2024 at 22:01, 1 year 5 months ago

Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax annonce le recrutement du premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn

Abivax Obefazimod Maladie De Crohn Phase 2b Essai Clinique
PRESS RELEASE

published on 10/03/2024 at 22:01, 1 year 5 months ago

Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai clinique de phase 2b avec obefazimod dans la maladie de Crohn
Abivax recrute premier patient pour Enhance-CD, essai clinique phase 2b obefazimod maladie Crohn. Etude 3 phases. Obefazimod, traitement prometteur

Abivax Obefazimod Maladie De Crohn Essai Clinique Enhance-CD
PRESS RELEASE

published on 10/03/2024 at 22:01, 1 year 5 months ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax announces enrollment of first patient in Phase 2b trial of Obefazimod for Crohn's Disease, aiming for convenient, effective treatment option with fewer daily burdens

Abivax Obefazimod Phase 2B Trial Immune Response Crohn's Disease
BRIEF

published on 10/03/2024 at 08:35, 1 year 5 months ago

Abivax Announces Positive Results for Obefazimod in Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Study Safety Analysis
BRIEF

published on 10/03/2024 at 08:35, 1 year 5 months ago

Abivax annonce des résultats positifs pour l'obéfazimod dans le traitement de la rectocolite hémorragique

Abivax Obefazimod Rectocolite Hémorragique Étude Clinique Analyse De Sécurité
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 5 months ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs pour obefazimod 25 mg chez les patients atteints de RCH modérée à sévère après 2 ans de maintenance. Analyse intermédiaire d'une étude de 6 ans

Abivax Obefazimod Efficacité RCH Rémission Clinique

Accesswire

Published on 03/23/2026 at 12:32, 9 minutes ago

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 11 minutes ago

Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 12:30, 11 minutes ago

High Tide Resources Announces Closing of Concurrent Non-Brokered Private Placements for Gross Proceeds of $8.3 Million
Published on 03/23/2026 at 12:20, 21 minutes ago

Guanajuato Silver Adds Veteran Mine Operator to Board of Directors
Published on 03/23/2026 at 12:15, 26 minutes ago

Snipp Interactive Secures US$3 Million Contract, Largest in Company History

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 12:33, 8 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 03/23/2026 at 12:29, 12 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 03/23/2026 at 11:44, 57 minutes ago

Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 1 hour 11 minutes ago

EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 11:06, 1 hour 34 minutes ago

Aroundtown SA: Release of a capital market information

Les Echos

Published on 03/23/2026 at 08:10, 4 hours 31 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 17 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 17 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE